专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO0053224A3 USE OF INHIBITORS OF ENDOTOXIN FOR THE TREATMENT OF HEART FAILURE AND OF CACHEXIA 审中-公开
标题翻译：内毒素抑制剂用于治疗心脏衰竭和慢性乙型肝炎的用途
公开(公告)号：WO0053224A3
公开(公告)日：2002-04-04
申请号：PCT/EP0002299
申请日：2000-03-09
申请人： MAX DELBRUECK CENTRUM , ANKER STEFAN , COATS ANDREW , VOLK HANS DIETER , RAUCHHAUS MATHIAS , SCHUMANN RALF REINER
发明人： ANKER STEFAN , COATS ANDREW , VOLK HANS-DIETER , RAUCHHAUS MATHIAS , SCHUMANN RALF REINER
IPC分类号： A61K31/575 , A61P9/04
CPC分类号： A61K31/575
摘要： A method of treating, preventing or ameliorating chronic heart failure or acute heart failure in a patient the method comprising administering to the patient an effective amount of: a compound that is able to bind to an endotoxin (lipopolysaccharide; LPS) molecule, for example LPS binding protein, BPI, lipoproteins, bile acids or an antibody capable of binding LPS, a compound that is able to bind to an endotoxin (lipopolysaccharide; LPS) molecule or bacterium in the gut, for example charcoal, a bile acid or Fuller's earth, an antibacterial agent that is substantially active in the gut, an agent that is able to inhibit the response by a cell to endotoxin (lipopolysaccharide; LPS), an agent that may form a barrier or that otherwise impedes translocation of bacteria or endotoxin (LPS) from the gut into the patient's circulation. A method of treating, preventing or ameliorating endotoxin-mediated immune activation in acute or chronic heart failure in a patient the method comprising administering to the patient an effective amount of: a compound that is able to bind to an endotoxin (lipopolysaccharide; LPS) molecule, for example LPS binding protein, BPI, lipoproteins, bile acids or an antibody capable of binding LPS, a compound that is able to bind to an endotoxin (lipopolysaccharide; LPS) molecule or bacterium in the gut, for example charcoal, a bile acid or Fuller's earth, an antibacterial agent that is substantially active in the gut, an agent that is able to inhibit the response by a cell to endotoxin (lipopolysaccharide; LPS), an agent that may form a barrier or that otherwise impedes translocation of bacteria or endotoxin (LPS) from the gut into the patient's circulation.
摘要翻译：一种治疗，预防或改善患者的慢性心力衰竭或急性心力衰竭的方法，该方法包括向患者施用有效量的：能够结合内毒素（脂多糖; LPS）分子的化合物，例如LPS 结合蛋白质，BPI，脂蛋白，胆汁酸或能够结合LPS的抗体，能够结合肠中的内毒素（脂多糖; LPS）分子或细菌的化合物，例如活性炭，胆汁酸或富勒氏土，在肠道中基本上具有活性的抗菌剂，能够抑制细胞对内毒素（脂多糖; LPS）的反应的试剂，可能形成屏障或另外阻碍细菌或内毒素（LPS）易位的药剂，从肠道到患者的流通。一种在患者急性或慢性心力衰竭中治疗，预防或改善内毒素介导的免疫激活的方法，该方法包括向患者施用有效量的：能够结合内毒素（脂多糖; LPS）分子的化合物，例如LPS结合蛋白，BPI，脂蛋白，胆汁酸或能够结合LPS的抗体，能够结合肠中的内毒素（脂多糖; LPS）分子或细菌的化合物，例如活性炭，胆汁酸或富勒的地球，在肠中基本上具有活性的抗菌剂，能够抑制细胞对内毒素（脂多糖; LPS）的反应的试剂，可能形成屏障或以其它方式阻碍细菌易位的药剂或内毒素（LPS）从肠道进入患者的循环。

2. 发明申请

WO0053165A3 USE OF INHIBITORS OF ENDOTOXIN FOR THE TREATMENT OF CHACHEXIA 审中-公开
标题翻译：内毒素抑制剂用于治疗CHACHEXIA的用途
公开(公告)号：WO0053165A3
公开(公告)日：2001-04-12
申请号：PCT/EP0002062
申请日：2000-03-09
申请人： MAX DELBRUECK CENTRUM , ANKER STEFAN , COATS ANDREW , VOLK HANS DIETER , SCHUMANN RALF REINER , PLAUTH MATHIAS , LOCHS HERBERT
发明人： ANKER STEFAN , COATS ANDREW , VOLK HANS-DIETER , SCHUMANN RALF REINER , PLAUTH MATHIAS , LOCHS HERBERT
IPC分类号： A61K31/575 , A61P9/04
CPC分类号： A61K31/575
摘要： The present invention relates to therapy and the use of agents in the therapy of cachexia and wasting syndromes due to diseases other than congestive heart failure. Cachexia occurs in a number of other chronic diseases, like liver cirrhosis, chronic obstructive pulmonary disease, chronic renal failure, diabetes, rheumatoid arthritis. Cachexia and weight loss are linked to inflammatory processes and they are linked to increased mortality and/or morbidity. Cytokine activation is a potential causal mechanism for the development of cachexia also in these other diseases. The invention describes a method of treating or ameliorating body wasting or cachexia in a patient with liver cirrhosis, chronic obstructive pulmonary disease, chronic renal failure, diabetes, rheumatoid arthritis in a patient. The method comprises administering to the patient an effective amount of a compound that is able to reduce the production, absorption and/or the effect of an endotoxin (lipopolysaccharide; LPS). The invention describes also a method of treating, preventing or ameliorating endotoxin-mediated immune activation in body wasting or cachexia in a patient with liver cirrhosis, chronic obstructive pulmonary disease, chronic renal failure, diabetes, rheumatoid arthritis. The method comprises administering to the patient an effective amount of a compound that is able to reduce the production, absorption and/or the effect of an endotoxin (lipopolysaccharide; LPS).
摘要翻译：本发明涉及治疗和使用药物治疗由于充血性心力衰竭以外的疾病引起的恶病质和浪费综合征。恶病质发生在许多其他慢性疾病，如肝硬化，慢性阻塞性肺疾病，慢性肾功能衰竭，糖尿病，类风湿性关节炎。恶病质和体重减轻与炎症过程有关，它们与死亡率和/或发病率增加有关。细胞因子激活是在这些其他疾病中发展恶病质的潜在因果机制。本发明描述了一种在患者中治疗或改善患有肝硬化，慢性阻塞性肺病，慢性肾功能衰竭，糖尿病，类风湿性关节炎的患者身体消瘦或恶病质的方法。该方法包括向患者施用有效量的能够降低内毒素（脂多糖; LPS）的产生，吸收和/或作用的化合物。本发明还描述了一种治疗，预防或改善患有肝硬化，慢性阻塞性肺疾病，慢性肾功能衰竭，糖尿病，类风湿性关节炎的患者体内呕吐或恶病质的内毒素介导的免疫激活的方法。该方法包括向患者施用有效量的能够降低内毒素（脂多糖; LPS）的产生，吸收和/或作用的化合物。

3. 发明专利

DE19729810A1 未知
公开(公告)号：DE19729810A1
公开(公告)日：1999-01-14
申请号：DE19729810
申请日：1997-07-11
申请人： MAX DELBRUECK CENTRUM
发明人： SCHUMANN RALF REINER , LAMPING NORBERT DR RER NAT
IPC分类号： C12N15/09 , A61K31/365 , A61K38/00 , A61K38/17 , A61K49/00 , A61P31/04 , A61P43/00 , C07K14/47 , C07K19/00 , C12N5/10 , A61K38/57
摘要： Therapeutic agent for the treatment of septicaemia, its preparation and use, with applications in the pharmaceutical industry and medicine. This therapeutic agent contains as essential element the lipopolysaccharide binding protein (LBP). Also disclosed are LBP variants, mutants and hybrid proteins. Murine or rabbit LBP may also be used, besides human LBP.

4. 发明专利

DK0999849T3 未知
公开(公告)号：DK0999849T3
公开(公告)日：2003-01-06
申请号：DK98928139
申请日：1998-04-04
申请人： MAX DELBRUECK CENTRUM
发明人： SCHUMANN RALF REINER , LAMPING NORBERT
IPC分类号： C12N15/09 , A61K31/365 , A61K38/00 , A61K38/17 , A61K49/00 , A61P31/04 , A61P43/00 , C07K14/47 , C07K19/00 , C12N5/10
摘要： A therapeutic agent for the treatment of septicemia, its preparation and use, with application in the pharmaceutical industry and medicine. This therapeutic agent contains essential element, the lipopolysaccharide binding protein (LBP). Also disclosed are LBP variants, mutants and hybrid proteins. Murine or rabbit LBP may also be used, besides human LBP.

5. 发明专利

DE19729810C2 未知
公开(公告)号：DE19729810C2
公开(公告)日：2000-01-13
申请号：DE19729810
申请日：1997-07-11
申请人： MAX DELBRUECK CENTRUM
发明人： SCHUMANN RALF REINER , LAMPING NORBERT
IPC分类号： C12N15/09 , A61K31/365 , A61K38/00 , A61K38/17 , A61K49/00 , A61P31/04 , A61P43/00 , C07K14/47 , C07K19/00 , C12N5/10 , A61K38/57 , A61K39/00
摘要： A therapeutic agent for the treatment of septicemia, its preparation and use, with application in the pharmaceutical industry and medicine. This therapeutic agent contains essential element, the lipopolysaccharide binding protein (LBP). Also disclosed are LBP variants, mutants and hybrid proteins. Murine or rabbit LBP may also be used, besides human LBP.

6. 发明专利

ES2183376T3 未知
公开(公告)号：ES2183376T3
公开(公告)日：2003-03-16
申请号：ES98928139
申请日：1998-04-04
申请人： MAX DELBRUECK CENTRUM
发明人： SCHUMANN RALF REINER , LAMPING NORBERT
IPC分类号： C12N15/09 , A61K31/365 , A61K38/00 , A61K38/17 , A61K49/00 , A61P31/04 , A61P43/00 , C07K14/47 , C07K19/00 , C12N5/10
摘要： A therapeutic agent for the treatment of septicemia, its preparation and use, with application in the pharmaceutical industry and medicine. This therapeutic agent contains essential element, the lipopolysaccharide binding protein (LBP). Also disclosed are LBP variants, mutants and hybrid proteins. Murine or rabbit LBP may also be used, besides human LBP.

7. 发明专利

AU3809900A Therapy and use of compounds in therapy 未知
公开(公告)号：AU3809900A
公开(公告)日：2000-09-28
申请号：AU3809900
申请日：2000-03-09
申请人： MAX DELBRUECK CENTRUM
发明人： ANKER STEFAN , COATS ANDREW , VOLK HANS-DIETER , SCHUMANN RALF REINER , PLAUTH MATHIAS , LOCHS HERBERT
IPC分类号： A61K31/575 , A61K31/00
摘要： A method of treating, preventing or ameliorating chronic heart failure or acute heart failure in a patient the method comprising administering to the patient an effective amount of: a compound that is able to bind to an endotoxin (lipopolysaccharide; LPS) molecule, for example LPS binding protein, BPI, lipoproteins, bile acids or an antibody capable of binding LPS, a compound that is able to bind to an endotoxin (lipopolysaccharide; LPS) molecule or bacterium in the gut, for example charcoal, a bile acid or Fuller's earth, an antibacterial agent that is substantially active in the gut, an agent that is able to inhibit the response by a cell to endotoxin (lipopolysaccharide; LPS), an agent that may form a barrier or that otherwise impedes translocation of bacteria or endotoxin (LPS) from the gut into the patient's circulation. A method of treating, preventing or ameliorating endotoxin-mediated immune activation in acute or chronic heart failure in a patient the method comprising administering to the patient an effective amount of: a compound that is able to bind to an endotoxin (lipopolysaccharide; LPS) molecule, for example LPS binding protein, BPI, lipoproteins, bile acids or an antibody capable of binding LPS, a compound that is able to bind to an endotoxin (lipopolysaccharide; LPS) molecule or bacterium in the gut, for example charcoal, a bile acid or Fuller's earth, an antibacterial agent that is substantially active in the gut, an agent that is able to inhibit the response by a cell to endotoxin (lipopolysaccharide; LPS), an agent that may form a barrier or that otherwise impedes translocation of bacteria or endotoxin (LPS) from the gut into the patient's circulation.

8. 发明专利

PT999849E 未知
公开(公告)号：PT999849E
公开(公告)日：2003-01-31
申请号：PT98928139
申请日：1998-04-04
申请人： MAX DELBRUECK CENTRUM
发明人： SCHUMANN RALF REINER , LAMPING NORBERT
IPC分类号： C12N15/09 , A61K31/365 , A61K38/00 , A61K38/17 , A61K49/00 , A61P31/04 , A61P43/00 , C07K14/47 , C07K19/00 , C12N5/10
摘要： A therapeutic agent for the treatment of septicemia, its preparation and use, with application in the pharmaceutical industry and medicine. This therapeutic agent contains essential element, the lipopolysaccharide binding protein (LBP). Also disclosed are LBP variants, mutants and hybrid proteins. Murine or rabbit LBP may also be used, besides human LBP.

9. 发明专利

AT223227T 未知
公开(公告)号：AT223227T
公开(公告)日：2002-09-15
申请号：AT98928139
申请日：1998-04-04
申请人： MAX DELBRUECK CENTRUM
发明人： SCHUMANN RALF REINER , LAMPING NORBERT
IPC分类号： C12N15/09 , A61K31/365 , A61K38/00 , A61K38/17 , A61K49/00 , A61P31/04 , A61P43/00 , C07K14/47 , C07K19/00 , C12N5/10
摘要： A therapeutic agent for the treatment of septicemia, its preparation and use, with application in the pharmaceutical industry and medicine. This therapeutic agent contains essential element, the lipopolysaccharide binding protein (LBP). Also disclosed are LBP variants, mutants and hybrid proteins. Murine or rabbit LBP may also be used, besides human LBP.

10. 发明专利

AU4105600A Therapy and use of compounds in therapy 未知
公开(公告)号：AU4105600A
公开(公告)日：2000-09-28
申请号：AU4105600
申请日：2000-03-09
申请人： MAX DELBRUECK CENTRUM
发明人： ANKER STEFAN , COATS ANDREW , VOLK HANS-DIETER , RAUCHHAUS MATHIAS , SCHUMANN RALF REINER
IPC分类号： A61K31/575 , A61K45/00
摘要： A method of treating, preventing or ameliorating chronic heart failure or acute heart failure in a patient the method comprising administering to the patient an effective amount of: a compound that is able to bind to an endotoxin (lipopolysaccharide; LPS) molecule, for example LPS binding protein, BPI, lipoproteins, bile acids or an antibody capable of binding LPS, a compound that is able to bind to an endotoxin (lipopolysaccharide; LPS) molecule or bacterium in the gut, for example charcoal, a bile acid or Fuller's earth, an antibacterial agent that is substantially active in the gut, an agent that is able to inhibit the response by a cell to endotoxin (lipopolysaccharide; LPS), an agent that may form a barrier or that otherwise impedes translocation of bacteria or endotoxin (LPS) from the gut into the patient's circulation. A method of treating, preventing or ameliorating endotoxin-mediated immune activation in acute or chronic heart failure in a patient the method comprising administering to the patient an effective amount of: a compound that is able to bind to an endotoxin (lipopolysaccharide; LPS) molecule, for example LPS binding protein, BPI, lipoproteins, bile acids or an antibody capable of binding LPS, a compound that is able to bind to an endotoxin (lipopolysaccharide; LPS) molecule or bacterium in the gut, for example charcoal, a bile acid or Fuller's earth, an antibacterial agent that is substantially active in the gut, an agent that is able to inhibit the response by a cell to endotoxin (lipopolysaccharide; LPS), an agent that may form a barrier or that otherwise impedes translocation of bacteria or endotoxin (LPS) from the gut into the patient's circulation.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式